Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning
- PMID: 14550810
- DOI: 10.1016/s0301-472x(03)00201-7
Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning
Abstract
Objective: We studied immune reconstitution in 51 recipients of HLA-identical hematopoietic cellular transplant (HCT) after nonmyeloablative conditioning compared to a reference group of 67 recipients after myeloablative conditioning.
Methods: Nonmyeloablative conditioning consisted of 2 Gy total-body irradiation+/-fludarabine and postgrafting cyclosporine and mycophenolate mofetil. All patients received G-CSF-mobilized peripheral blood mononuclear cells. Patients were followed with serial assessments of lymphocyte subset counts, antibody levels, virus-induced lymphoproliferation, and limiting-dilution assays for cytomegalovirus (CMV) T helper (T(H)) cells. Rates of infections over the first year after transplant were calculated.
Results: During the first 180 days, absolute lymphocyte subset counts were similar (except higher total and memory B cell counts on day 80 in nonmyeloablative patients). At 1 year, however, total and naïve CD4 counts, and naïve CD8 counts, were higher in myeloablative patients. The levels of antibodies were similar at all time points and after vaccinations. The function of CD4 cells assessed by virus-induced lymphoproliferation was similar. However, the absolute counts of CMV T(H) cells were higher at days 30 and 90 (p=0.002 and p=0.0003, respectively) after nonmyeloablative conditioning. The rates of definite infections were lower for nonmyeloablative patients during the first 90 days, but were higher later. The higher number of CMV-specific T cells days 30 and 90 after nonmyeloablative HCT coincided with a lower rate of CMV infections during that time.
Conclusion: The immunity of nonmyeloablative HCT recipients appears better than the immunity of conventional HCT recipients early, but not late, after HCT.
Similar articles
-
Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning.Biol Blood Marrow Transplant. 2006 Nov;12(11):1176-87. doi: 10.1016/j.bbmt.2006.07.004. Biol Blood Marrow Transplant. 2006. PMID: 17085311
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation.Hematology. 2003 Oct;8(5):303-11. doi: 10.1080/10245330310001612125. Hematology. 2003. PMID: 14530172
-
Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.Biol Blood Marrow Transplant. 2009 Jun;15(6):694-703. doi: 10.1016/j.bbmt.2009.02.009. Epub 2009 Apr 16. Biol Blood Marrow Transplant. 2009. PMID: 19450754 Free PMC article.
-
Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.Leukemia. 2006 Oct;20(10):1690-700. doi: 10.1038/sj.leu.2404335. Epub 2006 Jul 27. Leukemia. 2006. PMID: 16871276 Review.
Cited by
-
Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation.Haematologica. 2009 Aug;94(8):1101-8. doi: 10.3324/haematol.2008.003186. Haematologica. 2009. PMID: 19644142 Free PMC article.
-
How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation.Blood. 2016 Jun 2;127(22):2682-92. doi: 10.1182/blood-2016-01-634873. Epub 2016 Mar 11. Blood. 2016. PMID: 26968533 Free PMC article. Review.
-
Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review.Springer Semin Immunopathol. 2004 Nov;26(1-2):71-94. doi: 10.1007/s00281-004-0165-3. Epub 2004 Jul 29. Springer Semin Immunopathol. 2004. PMID: 15549304 Review.
-
Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34+-Selected to CD3/CD19-Depleted Grafts in a Retrospective Multicenter Study.Front Immunol. 2018 Aug 14;9:1841. doi: 10.3389/fimmu.2018.01841. eCollection 2018. Front Immunol. 2018. PMID: 30154788 Free PMC article.
-
Improving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantation.J Immunol Res. 2014;2014:631951. doi: 10.1155/2014/631951. Epub 2014 Apr 24. J Immunol Res. 2014. PMID: 24864269 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials